Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$3.88M | -$8.65M | -$15.0M | -$17.5M | -$19.7M | -$23.0M | -$30.6M | -$29.6M | -$26.6M | -$25.1M |
| Net income | -$3.93M | -$9.80M | -$11.9M | -$13.2M | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$26.0M | -$33.6M |
| EPS (diluted) | -$0.40 | -$0.53 | -$0.46 | -$1.95 | -$1.76 | -$0.59 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.77M | -$7.32M | -$12.2M | -$17.2M | -$17.8M | -$19.0M | -$27.6M | -$23.6M | -$23.9M | -$22.7M |
| Capital expenditures | $21.0K | $28.0K | $417K | $52.0K | $376K | $19.0K | $67.0K | $124K | $13.0K | $0.00 |
| Free cash flow | -$3.79M | -$7.35M | -$12.6M | -$17.3M | -$18.1M | -$19.0M | -$27.7M | -$23.7M | -$23.9M | -$22.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.01M | $7.71M | $7.13M | $10.7M | $15.2M | $70.9M | $43.1M | $23.6M | $4.28M | $8.88M |
| Total assets | $16.4M | $19.5M | $19.6M | $25.2M | $29.0M | $84.1M | $57.4M | $38.2M | $16.9M | $22.1M |
| Total liabilities | $1.43M | $2.37M | $5.31M | $9.66M | $11.3M | $5.10M | $5.23M | $12.1M | $5.72M | $7.12M |
| Shareholders' equity | $15.0M | $17.1M | $14.3M | $15.6M | $17.8M | $79.0M | $52.2M | $30.9M | $11.2M | $15.0M |
| Retained earnings | -$4.67M | -$14.5M | -$26.4M | -$39.6M | -$56.9M | -$72.8M | -$102M | -$132M | -$146M | -$206M |
| Shares (wtd avg diluted) | 12.2M | 21.5M | 28.5M | 7.62M | 11.5M | 26.9M | 1.91M | 1.98M | 138K | 1.18M |
Every figure is extracted from Moleculin Biotech, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.